Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review)

Oncology Reports
Ioannis S VizirianakisMarios Spanakis

Abstract

The existing tumor heterogeneity and the complexity of cancer cell biology critically demand powerful translational tools with which to support interdisciplinary efforts aiming to advance personalized cancer medicine decisions in drug development and clinical practice. The development of physiologically based pharmacokinetic (PBPK) models to predict the effects of drugs in the body facilitates the clinical translation of genomic knowledge and the implementation of in vivo pharmacology experience with pharmacogenomics. Such a direction unequivocally empowers our capacity to also make personalized drug dosage scheme decisions for drugs, including molecularly targeted agents and innovative nanoformulations, i.e. in establishing pharmacotyping in prescription. In this way, the applicability of PBPK models to guide individualized cancer therapeutic decisions of broad clinical utility in nanomedicine in real-time and in a cost-affordable manner will be discussed. The latter will be presented by emphasizing the need for combined efforts within the scientific borderlines of genomics with nanotechnology to ensure major benefits and productivity for nanomedicine and personalized medicine interventions.

References

Jul 18, 2002·Nature Reviews. Drug Discovery·Kevin BraeckmansJoseph Demeester
Apr 6, 2004·Trends in Pharmacological Sciences·Magnus Ingelman-Sundberg
Jun 26, 2004·PharmacoEconomics·Christopher R Flowers, David Veenstra
Aug 12, 2004·Proceedings of the National Academy of Sciences of the United States of America·Vasilis NtziachristosRalph Weissleder
Jan 6, 2005·Journal of the National Cancer Institute·Yan JinDavid A Flockhart
Mar 27, 2007·International Journal of Pharmaceutics·Rüdiger GröningAlexander C Jansen
Jul 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qingyu ZhouJames M Gallo
Oct 25, 2007·Clinical Pharmacology and Therapeutics·L ZhangO C Farokhzad
Sep 5, 2008·Environmental Science & Technology·Pinpin LinRaymond S H Yang
Nov 28, 2008·International Journal of Toxicology·Michael L ShelleyCharles Bleckmann
Jan 20, 2009·Current Pharmaceutical Design·Paul Debbage
Feb 19, 2009·European Journal of Human Genetics : EJHG·David GurwitzDolores Ibarreta
Sep 1, 2009·International Journal of Pharmaceutics·Pi XitianWen Zhiyu
Oct 29, 2009·Cancer Research·Paolo CastorinaThomas S Deisboeck
Nov 17, 2009·Drug Discovery Today·Stewart Bates
Nov 26, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·Geoffrey S Ginsburg, Huntington F Willard
Apr 14, 2010·Methods in Molecular Biology·Weiwei GaoOmid C Farokhzad
Apr 15, 2010·Chemical Reviews·Vasilis Ntziachristos, Daniel Razansky
Apr 27, 2010·Pharmacogenomics·Katherine Payne, Fatiha H Shabaruddin
May 22, 2010·Trends in Pharmacological Sciences·Kwangmi AhnRongling Wu
Jun 5, 2010·PLoS Computational Biology·Curtis Huttenhower, Oliver Hofmann
Jun 11, 2010·Nature Reviews. Cancer·Timothy A YapJohann S de Bono
Jun 22, 2010·Molecular Diagnosis & Therapy·Kewal K Jain
Sep 15, 2010·Nature Reviews. Clinical Oncology·Rakesh K Jain, Triantafyllos Stylianopoulos
Sep 22, 2010·Annual Review of Pharmacology and Toxicology·Malcolm RowlandGeoffrey Tucker
Oct 13, 2010·PharmacoEconomics·William B WongDavid L Veenstra
Oct 23, 2010·Advanced Drug Delivery Reviews·Sarbari Acharya, Sanjeeb K Sahoo
Nov 13, 2010·International Journal of Pharmaceutics·Klaus Wening, Jörg Breitkreutz
Nov 26, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Ioannis S Vizirianakis
Jan 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·James W BaishRakesh K Jain
Jan 29, 2011·Clinical Pharmacology and Therapeutics·M V Relling, T E Klein
Jan 29, 2011·Clinical Pharmacology and Therapeutics·M V RellingUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Mar 18, 2011·Clinical Pharmacology and Therapeutics·J J SwenH-J Guchelaar
Apr 22, 2011·Clinical Pharmacology and Therapeutics·U Amstutz, B C Carleton

❮ Previous
Next ❯

Citations

Sep 21, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Clara HartmanshennIoannis P Androulakis
Jul 3, 2020·Journal of Personalized Medicine·Marios SpanakisEvridiki Patelarou
Apr 13, 2019·Current Opinion in Biotechnology·Jacob D DavisEberhard O Voit

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.